International Isotopes Inc. (INIS) reported its financial results for the second quarter and first half of 2025, revealing a total revenue of $3.66 million for the three months ending June 30, 2025, a 15% increase from $3.17 million in the same period of 2024. For the first half of 2025, revenue reached $6.89 million, up 14% from $6.07 million year-over-year. The company’s gross profit for the second quarter was $2.14 million, reflecting a 6% increase from $2.02 million in the prior year. However, the net loss for the quarter narrowed to $160,785 compared to a loss of $233,445 in the same quarter of 2024.
The increase in revenue was primarily driven by significant growth in the Nuclear Medicine Standards segment, which saw sales rise by 149% to $1.01 million, while the Cobalt Products segment also experienced a 14% increase in sales. Conversely, the Theranostics Products segment reported a 12% decline in sales, attributed to a lack of additional sales that had previously occurred due to a competitor's outage in the prior year. The Medical Device Products segment, newly established, generated $58,089 in sales during the quarter.
Operationally, the company’s total operating expenses rose by 4% to $2.28 million in the second quarter, largely due to increased salaries and contract labor costs associated with a growing workforce. Research and development expenses decreased significantly, reflecting a reduction in legal costs. The company’s cash and cash equivalents stood at $1.86 million as of June 30, 2025, down from $1.95 million at the end of 2024, while net cash provided by operating activities increased to $310,446 from $288,597 in the prior year.
Strategically, INIS has focused on its core business segments and is actively pursuing new opportunities, particularly in the Medical Device segment, which includes products acquired from AMICI, Inc. The company has also entered into a joint venture with Alpha Nuclide Inc. to manufacture and distribute its Theranostics Products in China. Additionally, INIS is in the process of selling its Fluorine Products segment, with a potential closing date set for March 31, 2026, contingent on various conditions. The anticipated proceeds from this sale could total $12.5 million.
Looking ahead, the company expects that its current cash balance, along with cash generated from operations and potential equity or debt financing, will be sufficient to fund its operations for the next twelve months. However, management has noted that future liquidity and capital funding requirements will depend on various factors, including market conditions and the success of its strategic initiatives.
About INTERNATIONAL ISOTOPES INC
International Isotopes Inc. produces and distributes nuclear medicine radiopharmaceuticals, calibration standards, and cobalt-60 products for medical, industrial, and research markets. The company offers FDA-approved radiopharmaceuticals, develops medical devices, and operates in regulated environments with a focus on safety and compliance. Its core business includes manufacturing, product development, and strategic partnerships in global markets, emphasizing innovation, regulatory adherence, and expanding market share in isotope applications.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.